Essays12 min read
Where are all the ribosome drugs?
The ribosome is simultaneously the most successfully drugged target in the history of medicine and one of the least.
Jonathan Ouyang · also on Substack and LessWrong
Ribosomes rule life. They probably enabled life to exist in the first place, by being responsible for 100% of protein synthesis; we define species using them (archaea were discovered by 16S rRNA phylogeny) [1]; they’re autocatalytic universal constructors responsible for the limit on replication speed [2], [3], [4], [5], [6], and their biogenesis is a major determinant of most cellular processes (e.g. transcription, translation, splicing, and metabolism). [7], [8], [9], [10]1 If the human body is a scaffold that supports the brain, the cell is a scaffold that supports ribosomes.
The majority of antibiotic classes target the ribosome in some fashion. [11], [12], [13]2 Ribosomes and their regulation are implicated not just in so-called ribosomopathies but also in fundamental malfunctions in cancer, neurodegenerative, and geropathological diseases. [14], [15], [16], [17], [18], [19] The ribosome is simultaneously the most successfully drugged target in the history of medicine and one of the least. So, then, where are all the ribosome drugs?
From sledgehammers to levers
The use of the first ribosome-targeting drugs can be traced to before 550 CE, where ancient Sudanese societies consumed beverages fermented with Streptomyces, a bacteria that produces tetracycline [20], [21]3, which binds the 30S subunit of the (bacterial) ribosome to inhibit translation, and now names an entire class of antibiotics. [11], [12] Other ribosome-targeting antibiotics include chloramphenicol, the aminoglycosides, spectinomycins, macrolides, oxazolidinones, lincosamides, streptogramins, pleuromutilins… all of which are generally broad-spectrum protein synthesis inhibitors and which therefore shut down cellular activity. [22]4 Although the mechanisms of actions of these drugs are varied, all of them act via disruption of some key step during canonical translation.
These “sledgehammers” work spectacularly for two reasons: one, they are relatively unselective (targeting all ribosomes), so the effect is brutal and difficult to mitigate, and two, human ribosomes are sufficiently divergent from bacterial that we typically escape the direct effects of these drugs (this is not always the case – mitoribosomes are very close to bacterial and some antibiotics are contraindicated for people with sufficiently similar mitoribosomes). [23], [24]5 This is great if we want to effectively nuke anything with prokaryotic ribosomes! It’s less great if we want effective medicine targeting a pathology, where we want to leverage this power with more precision. For example, cycloheximide, the eukaryotic functional equivalent of chloramphenicol or tetracycline, is firmly a laboratory reagent, way too toxic for any medical application. So how do we go from sledgehammers to new levers – new knobs of control – of human biology?
One way is to continue to try and separate “kinds” of human cells via physiology – basically, cancer. Cancer cells are highly active, and thus have extremely active translation; like most chemotherapies, this allows for a degree of selectivity. Nevertheless, this is not very selective – the only FDA-approved indiscriminate human protein synthesis inhibitor, omacetaxine (or Synribo) carries with it a laundry list of side effects that mimic hereditary ribosomopathies (severe and fatal myelosuppression: thrombocytopenia, neutropenia, anemia). [15], [25]
PF846 (PF-06446846) is one such attempt to modulate the human ribosome with more finesse. PF846 was an optimized version of the only result of a 2.5-million-compound screen, and whose mechanism was entirely unintentional. [26], [27], [28]6 Unlike the broadly inhibiting bacterial antibiotics, PF846 binds in a eukaryote-specific pocket in the exit tunnel and interacts with the nascent peptide, with shocking substrate specificity – a translation screen with ribosome profiling determined just 22 PF846-sensitive genes. [29], [27]7 Originally pursued for inhibition of PCSK9, a major regulator of plasma LDL cholesterol, it was abruptly discontinued in 2016 during Phase 1. [27], [30], [31]
A decade of silence
In the next few years, much progress is made on understanding PF846 and its relatives. Better chemistry is made, more characterization is done, structures are solved, and mechanisms mapped. [28], [30], [29], [32] Nevertheless, translation modulation remains dark. Why?
First, the fundamental science simply wasn’t quite there. Determining the targets of PF846-like drugs was literally shooting in the dark and praying, the opposite of the target → assay → chemistry pipeline. There seemed to be no pattern whatsoever between the targets. [26], [27]8 Furthermore, beyond predicting the effect/no-effect binary, PF846 can stall elongation, arrest termination, or even enhance translation. [29], [32] Without predictive capability, a rational approach simply wasn’t possible, and the nature of the mechanism meant that the chemical activity landscape was ridden with steep, steep cliffs. [27], [28], [33] A similar drug, PF8503, also affected PCSK9, but with off-target hits almost entirely different. [34]
Other key portions of the basic-to-clinical pathways were missing. The key assay technique for translation modulation, ribosome profiling (or Ribo-seq), was still unstandardized and full of yet-unknown confounds. [35], [36], [37], [38] Structures were simply too low-resolution (3.0+ angstroms) to do structure-guided design against a highly dynamic substrate. [29], [39] And the mechanistic model behind the action was still unknown, leaving open all kinds of questions about cryptic activity. [27], [34], [29], [32]
Second, a series of unfortunate coincidences repeatedly killed promising drugs. PF846 was discontinued due to a strategic business decision, perhaps due to the existence of the same-indication and later-failed Phase 3 bococizumab. [31], [40] A series of other drugs are discontinued through no fault of their own. Selective inhibition of eIF4A with zotatifin – translation initiation – is orphaned from the failure of tomivosertib, a MNK inhibitor. [41], [42], [43] In both these cases, the drugs continue to produce excellent science, even years later – including by the companies that discontinued them! [28], [29], [44], [45] More recently, an eIF2B activator works perfectly mechanistically, but has no effect on any clinical endpoint in ALS. [46], [47], [48] This can be broadly summed up as “great mechanism, wrong indication” – a hallmark of a field that didn’t understand where the ribosome is truly root.
Lastly, weird things happen when you modulate something so fundamental. Zotatifin, an oncology drug, had separate promising effects and entered trials for COVID-19. [49], [50], [51] With PF846/PF8503, the pathways underlying cellular response to stalling, ribosome quality control, had completely counterintuitive effects on the pharmacology. [34]9 CX-5461, another oncology drug targeting ribosome biogenesis, turns out to be effective almost entirely through TOP2B, a DNA topoisomerase. [52], [53]10 Drugs approved for ribosomopathies, the most canonical, “duh” indication for ribosome-as-a-target, don’t target the ribosome at all. In del(5q) MDS, a disease where ribosomal protein RPS14 is haploinsufficient (leading to defective ribosome assembly, p53 activation, and impaired erythropoiesis), the wildly effective lenalidomide has nothing to do with the ribosome, instead causing the degradation of casein kinase 1α. [14], [54], [55], [56] Diamond-Blackfan anemia, the prototypic ribosomopathy, has had no new approved therapy since 1951, and the three leading candidates act on calmodulin/p53, iron, and mTOR, not the ribosome. [57], [58], [59], [60], [61], [62]
So: nine years of little clinical output, and a field that just kept missing the right level of ribosome regulation. What now?
An explosive new era
In the next two years (2024-2026), the last decade of science coalesces into a universe of possibilities. High resolution structures of dozens of functional and native ribosome states are captured. [63], [64], [65] Ribosome quality control is significantly elucidated, clarifying previously inexplicable phenotypic results. [66], [67], [68], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [34], [220], [221] New layers of ribosome control are found in cryptic-but-essential translation activities, and more and more pathologies, especially aging-related and immunological, are directly linked to the ribosome. [85], [86], [87], [17], [19], [88], [89] tRNA manipulation matures, as do half a dozen other, new levers of the ribosome. [90], [91], [92], [93], [94], [95] Ribo-seq matures and results in powerful predictive tools. [96], [97], [98], [99], [100], [101] Engineering problems with the nascent peptide at the exit tunnel are replaced with the advent of rationally-designable peptidyl-transferase center drugs (Interdictor series). [15] Next-generation activators of eIF2B are now in development (Phase 1-2) for Vanishing White Matter (granted Breakthrough Therapy designation) and Charcot-Marie-Tooth (Type 2D). [102], [103], [104] AstraZeneca releases an inhibitor and, more crucially, an activator of the ribosome-associated Integrated Stress Response pathway, allowing bidirectional modulation for the first time. [105], [106], [107] Zotatifin is revived in a Phase I/II combination therapy for advanced breast cancer. [108], [109], [110] Each success continues to showcase the necessary reframe of the field – the finesse – needed when targeting something as versatile as the ribosome. Activation and inhibition of various ribosome-related systems are both beneficial and both needed, dependent on combinations of organ, cell type, and disease specific contexts. [15], [102], [105]
A taxonomy of the ribosomal future
Nails: reframing old indications as new ribosomopathies
1. Neurodegeneration
Neurodegeneration and especially aging-related neurodegeneration are perhaps one of the most intrinsically tied classes of pathologies to ribosomal dysfunction. [111], [16], [17], [19], [217], [218] Neurons are unique in being highly translationally active, being post-mitotic (i.e., very slow ribosomal turnover), and are large (axons can be over a meter long!), meaning that regulation has outsized importance for the local environment. [112], [113], [114] It’s no surprise that proteostatic diseases are disproportionately neurological! [115], [116], [117] In particular, recent work shows that the molecular age of ribosomes impairs elongation on certain sequences, and that this is linked to aging and neurodegenerative phenotypes in model organisms. [19], [17] These diseases are commonplace (ALS/FTD, Alzheimer’s, Huntington’s, etc.), and also have very very little in the way of working therapeutics. [118], [119], [120], [121], [122] Perhaps the reason for this is that interventions downstream of the ribosome are too slow!
2. Cancer
In an opposite fashion to neurodegeneration, cancer cells typically become dependent on abnormally active translation, but nevertheless also become sensitized to proteostatic stress. [123], [124], [125], [126], [127], [128], [129], [130], [44], [45], [131], [15] Because cancer cells maintain a constant, high level of translation, a level of selectivity can be achieved even with indiscriminate inhibitors of the ribosome, such as omacetaxine. [132], [133], [134] However, this therapeutic window (the gap between healthy and cancerous cells) is significantly smaller, limiting the efficacy of this sledgehammer approach. [135], [136], [137] For this reason, omacetaxine is the only approved chemotherapeutic agent directly targeting the ribosome. [15], [138] Cancer nevertheless remains an attractive and logical target for more fine-tuned approaches to translation modulation. [44], [45], [15]
3. Ribosomopathies
The canonical ribosomopathies, ironically, remain poorly treated at their root. [57], [139] Unlike cancer or neurodegeneration, ribosomopathies are simple in their mechanism, typically revolving around ribosome assembly defects during biogenesis. [140], [141], [142], [143] However, current treatments are almost all entirely downstream of the ribosome and manage phenotypic defects in consequence. [57], [139] Instead of these highly imperfect approaches, can we modulate at the ribosome level to properly restore function?
4. Immunology
The links between immunological response and ribosome (and ribosome quality control) are being increasingly elucidated. [84], [89], [88] Beyond modulation of the immunopeptidome, the “dark proteome,” noncanonical translation, and miniproteins, translation disruption is frequent in infection and infection response – for example, ribosomes are commonly co-opted by viruses for replication. [86], [144], [145], [146], [147] These pathways, such as interferon-RNase L, intersect with ribosome quality control to regulate cell fate. [88], [89], [84]
5. Antibacterials
We are in an antibiotic resistance crisis. [148], [149] Most classes of antibiotics target the ribosome, yes, but most of them are borrowed from evolution – other bacteria. [13], [11], [150] Of the rationally designed ones, all bind in the same few binding pockets targeted by nature. [151], [152], [153], [11] The ribosome is a staggering 2.5MDa machine, full of new druggable pockets entirely untapped. [154], [155], [156], [157], [158] Could structure-guided rational design provide more, diverse, and new-to-nature antibacterials? [151], [152], [153] Beyond elongation, can we mimic some of our human modalities and target initiation, biogenesis, or ribosome-associated pathways – all of which are entirely nascent in the current landscape? [159], [160], [161], [162], [163]
Hammers: ribosomal drug modalities with finesse
1. RQC & sensors
Ribosome quality control (RQC) is a powerful and clinically untapped layer of biology. [164], [165], [166], [167], [168], [169], [170], [171], [172], [111], [16], [173], [77], [174], [175], [176], [84], [89], [128], [88], [217], [218], [219], [221] In neurodegeneration, enhancement of RQC protein ZNF598 rescues disease phenotype in C9ORF72 ALS patient-derived neuronal culture, and an ALS-associated ZNF598 variant impairs RQC; [164] on the converse, reduction of ZNF598 can alleviate other APP-associated pathologies. [171] Other proteins in the canonical RQC pathway are also attractive targets, such as NEMF/Rqc2 and Listerin, and are also defective in pathologies such as hereditary motor neuron disease. [16], [173], [111], [166], [220] ZAKα is a powerful ribosome stall sensor capable of initiating apoptosis, implicated in leukemia, ulcerative colitis, and inflammatory pathways. [84], [177], [178], [179], [180], [181], [182], [218] Along with the sentinel protein GCN2 (most well-known for the Integrated Stress Response, or ISR, another fundamental ribosome-mediated decision pathway), RQC is implicated in macrophage hyperinflammation and antiviral response. [84], [183], [184], [185], [186], [89] The Pelota-HBS1L RQC complex has recently been successfully targeted in preclinical models in an oncology indication. [187], [188], [189]
Overall, broad modulation of the disease landscape is now mechanistically achievable via drugging of the various RQC systems. [164], [171], [189], [219] In particular, if the disease is proteostatic in nature, RQC enhancement is a promising new modality, and if the disease involves abnormal translation or ribosome-linked secondary pathways, RQC disruption is a major candidate. [164], [166], [171], [128], [189] I believe that a major RQC drug for a neurodegenerative indication will pass the preclinical stage in the next five years (by October 2031), and Phase 1 for oncology.
2. Initiation
Modulating initiation of translation, as the most mature current modality, is perhaps the most probable mechanism to first become clinically successful. [41], [46], [102] Beyond significant proof of concept and existing validation, initiation related pathways, like the ISR, are perhaps the easiest to drug, and design against mRNA sequence allows transcript selectivity to easily fall out, solving the selectivity problem as well. [190], [191], [41], [44], [105] For example, as mentioned previously, drugs targeting initiation proteins eIF4F, eIF2B, and the eIF2α complex have shown great success in preclinical and early clinical. [45], [46], [102], [192] I believe that selective manipulation of initiation will pass Phase 3 in 8 years (by October 2034).
3. Elongation
Elongation likewise now has significant progress and avoids some of the limitations of initiation drugging, which involves design against RNA. [29], [15], [191] Targeting the nascent peptide allows for advantageous selective capability on the basis of the much more discriminative 20 amino acids, instead of the much more difficult RNA tertiary structure. [29], [15], [44] The interdictor series shows great promise in this regard, allowing for sequence-dependent selectivity on the basis of linear protein sequence. [15] This, beyond being potentially a universal target of any translated protein, also removes problems with targeting intrinsically disordered proteins (as the ribosome linearizes the proteome, and also is guaranteed to be in complex with every protein). [29], [15] Mutations also require changes in the ribosome, a famously invariant molecule (hence success of antibiotics), or missense mutations in the target protein, a significant advantage over similar modality therapeutics. [29], [32], [34] I believe that selective manipulation of elongation will pass Phase 2 in 5 years (by October 2031).
4. tRNA
A full 11% of genetic disease-causing mutations are nonsense mutations; an easy way to rescue these is to modulate tRNA decoding fidelity to suppress the stop codon and promote near-cognate tRNA incorporation, causing readthrough. [193], [194], [195], [196] Many of these exist, but suffer from selectivity issues – Ataluren, a small-molecule readthrough drug, recently was discontinued for two indications in cystic fibrosis and nonsense-mutation Duchenne muscular dystrophy after approval failure by both the FDA and EMA. [197], [198], [199] Recent advances elucidating the more precise mechanism of readthrough will enhance rational design. [200], [201], [202] Other approaches include gene therapies expressing engineered tRNAs for similar purposes and general modulation of tRNA synthetases. [203], [92], [93], [94], [204] I believe that next-generation Ataluren-type decoding modulators will pass Phase 2 in 3 years (by October 2029), and that engineered tRNA therapies will pass Phase 2 in 5 years (by October 2031).
5. Accelerators
Restoration of ribosomal activity is likely to become the most impactful mechanism of ribosome targeting drugs. Although this is less of a mechanism and more of a broad direction, impairment of translation is so fundamental that modalities which counteract it are likely to be essential across many pathologies and aging. [205], [206], [207], [17], [208], [209], [210], [211], [212], [213], [214], [93], [90], [92], [215], [216] Beyond genetic haploinsufficiencies and ribosomopathies, reversing defects in initiation and elongation is directly tied to neurodegenerative and other pathological phenotypes in aging and stress conditions. [205], [206], [208], [207], [212] As with all therapies, differential and tissue-specific activity will be crucial. [222] The aforementioned eIF2B activators, restorers of initiation, recently received Breakthrough Therapy Designation. [102] Here, I predict a therapy which conducts strict enhancement of the ribosome’s fidelity will become a cornerstone longevity drug, passing Phase 1 in 6 years (by October 2032), and a therapy which restores ribosome assembly defects in canonical ribosomopathies will pass Phase 2 in 5 years (by October 2031).
Notes
- 1.S. cerevisiae, rapid growth: rRNA ≥60% transcription; RP ≈50% Pol II initiations, ≈30% mRNA, ≈90% intron-containing transcript production (Li, Nierras & Warner, 1999; Ares, Grate & Pauling, 1999). S. pombe, EMM2, 30 °C: RP = 46% mRNA (Chikashige et al., 2015). E. coli, fast growth: protein + rRNA >80% biomass-production ATP (Maitra & Dill, 2015).
- 2.Butler et al. (2024), Table 1; β-lactamase inhibitors excluded: ribosome = 9/33; translation = 11/33; cell envelope = 11/33.
- 3.Slightly exaggerated for effect; fermented beverages are a hypothesized source of high skeletal tetracycline levels (Bassett et al., 1980; Nelson et al., 2010).
- 4.Although even here, these drugs exhibit some context-dependent activity (Choi et al., 2019/2020).
- 5.MT-RNR1 m.1555A>G / m.1494C>T / m.1095T>C: “aminoglycoside antibiotics are relatively contraindicated” (CPIC, 2021).
- 6.Original hit before optimization: R-IMPP (PF-00932239) (McClure et al., 2017).
- 7.Huh7 cells: 22 at 60 min timepoint; 44 at 10 min timepoint (Lintner et al., 2017).
- 8.“stalling cannot be predicted by a simple primary structure motif” (Lintner et al., 2017).
- 9.NEMF/LTN1 or PELO/HBS1L knockdown → ↑ fitness under PF8503 (Liaud et al., 2019).
- 10.TOP2A also inhibited; TOP2B preference ~2-4× in vitro (Pan et al., 2021).
Sources
- 1.Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proc Natl Acad Sci U S A. 1977;74(11):5088-90. doi:10.1073/pnas.74.11.5088
- 2.Reuveni S, Ehrenberg M, Paulsson J. Ribosomes are optimized for autocatalytic production. Nature. 2017;547(7663):293-7. doi:10.1038/nature22998
- 3.Scott M, Gunderson CW, Mateescu EM, Zhang Z, Hwa T. Interdependence of cell growth and gene expression: origins and consequences. Science. 2010;330(6007):1099-102. doi:10.1126/science.1192588
- 4.Belliveau NM, Chure G, Hueschen CL, Garcia HG, Kondev J, Fisher DS, et al. Fundamental limits on the rate of bacterial growth and their influence on proteomic composition. Cell Syst. 2021;12(9):924-944.e2. doi:10.1016/j.cels.2021.06.002
- 5.Roy A, Goberman D, Pugatch R. A unifying autocatalytic network-based framework for bacterial growth laws. Proc Natl Acad Sci U S A. 2021;118(33):e2107829118. doi:10.1073/pnas.2107829118
- 6.Goberman D, Roy A, Pugatch R. Slowing translation to avoid cellular depletion of active ribosomes at slow growth rates. Phys Rev Res. 2026;8(1):013226. doi:10.1103/3nwf-b259
- 7.Li B, Nierras CR, Warner JR. Transcriptional elements involved in the repression of ribosomal protein synthesis. Mol Cell Biol. 1999;19(8):5393-404. doi:10.1128/mcb.19.8.5393
- 8.Ares M Jr, Grate L, Pauling MH. A handful of intron-containing genes produces the lion's share of yeast mRNA. RNA. 1999;5(9):1138-9. doi:10.1017/s1355838299991379
- 9.Chikashige Y, Arakawa S, Leibnitz K, Tsutsumi C, Mori C, Osakada H, et al. Cellular economy in fission yeast cells continuously cultured with limited nitrogen resources. Sci Rep. 2015;5(1):15617. doi:10.1038/srep15617
- 10.Maitra A, Dill KA. Bacterial growth laws reflect the evolutionary importance of energy efficiency. Proc Natl Acad Sci U S A. 2015;112(2):406-11. doi:10.1073/pnas.1421138111
- 11.Paternoga H, Crowe-McAuliffe C, Bock LV, Koller TO, Morici M, Beckert B, et al. Structural conservation of antibiotic interaction with ribosomes. Nat Struct Mol Biol. 2023;30(9):1380-92. doi:10.1038/s41594-023-01047-y
- 12.Marks J, Kannan K, Roncase EJ, Klepacki D, Kefi A, Orelle C, et al. Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center. Proc Natl Acad Sci U S A. 2016;113(43):12150-5. doi:10.1073/pnas.1613055113
- 13.Butler MS, Vollmer W, Goodall ECA, Capon RJ, Henderson IR, Blaskovich MAT. A Review of Antibacterial Candidates with New Modes of Action. ACS Infect Dis. 2024;10(10):3440-74. doi:10.1021/acsinfecdis.4c00218
- 14.Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-9. doi:10.1038/nature06494
- 15.Diamond PD, Sauer PV, Holm M, Swanson-Swett CJ, Ferguson L, Bratset NM, et al. Context-dependent translation inhibition as a cancer therapeutic modality. Nat Commun. 2026;17(1):1963. doi:10.1038/s41467-026-69891-2
- 16.Martin PB, Kigoshi-Tansho Y, Sher RB, Ravenscroft G, Stauffer JE, Kumar R, et al. NEMF mutations that impair ribosome-associated quality control are associated with neuromuscular disease. Nat Commun. 2020;11(1):4625. doi:10.1038/s41467-020-18327-6
- 17.Di Fraia D, Marino A, Lee JH, Kelmer Sacramento E, Baumgart M, Bagnoli S, et al. Altered translation elongation contributes to key hallmarks of aging in the killifish brain. Science. 2025;389(6759):eadk3079. doi:10.1126/science.adk3079
- 18.Stein KC, Morales-Polanco F, van der Lienden J, Rainbolt TK, Frydman J. Ageing exacerbates ribosome pausing to disrupt cotranslational proteostasis. Nature. 2022;601(7894):637-42. doi:10.1038/s41586-021-04295-4
- 19.Botello JF, Jiang L, Metzger PJ, Comi TJ, Abu-Alfa AA, Yu Q, et al. Ribosome Molecular Aging Shapes Translation Dynamics. bioRxiv [Preprint]. 2026 Mar 9 [cited 2026 Oct 15]. doi:10.64898/2026.03.08.710403
- 20.Bassett EJ, Keith MS, Armelagos GJ, Martin DL, Villanueva AR. Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350). Science. 1980;209(4464):1532-4. doi:10.1126/science.7001623
- 21.Nelson ML, Dinardo A, Hochberg J, Armelagos GJ. Brief communication: Mass spectroscopic characterization of tetracycline in the skeletal remains of an ancient population from Sudanese Nubia 350–550 CE. Am J Phys Anthropol. 2010;143(1):151-4. doi:10.1002/ajpa.21340
- 22.Choi J, Marks J, Zhang J, Chen DH, Wang J, Vázquez-Laslop N, et al. Dynamics of the context-specific translation arrest by chloramphenicol and linezolid. Nat Chem Biol. 2020;16(3):310-7. doi:10.1038/s41589-019-0423-2
- 23.McDermott JH, Wolf J, Hoshitsuki K, Huddart R, Caudle KE, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype. Clin Pharmacol Ther. 2022;111(2):366-72. doi:10.1002/cpt.2309
- 24.Bibel B, Raskar T, Couvillion M, Lee M, Kleinman JI, Takeuchi-Tomita N, et al. Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics. Nucleic Acids Res. 2025;53(3):gkaf046. doi:10.1093/nar/gkaf046
- 25.US Food and Drug Administration. SYNRIBO (omacetaxine mepesuccinate): prescribing information [Internet]. 2012 [cited 2026 Oct 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf
- 26.Petersen DN, Hawkins J, Ruangsiriluk W, Stevens KA, Maguire BA, O'Connell TN, et al. A Small-Molecule Anti-secretagogue of PCSK9 Targets the 80S Ribosome to Inhibit PCSK9 Protein Translation. Cell Chem Biol. 2016;23(11):1362-71. doi:10.1016/j.chembiol.2016.08.016
- 27.Lintner NG, McClure KF, Petersen D, Londregan AT, Piotrowski DW, Wei L, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2017;15(3):e2001882. doi:10.1371/journal.pbio.2001882
- 28.Londregan AT, Wei L, Xiao J, Lintner NG, Petersen D, Dullea RG, et al. Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. J Med Chem. 2018;61(13):5704-18. doi:10.1021/acs.jmedchem.8b00650
- 29.Li W, Ward FR, McClure KF, Chang ST, Montabana E, Liras S, et al. Structural basis for selective stalling of human ribosome nascent chain complexes by a drug-like molecule. Nat Struct Mol Biol. 2019;26(6):501-9. doi:10.1038/s41594-019-0236-8
- 30.McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, et al. Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis. Angew Chem Int Ed Engl. 2017;56(51):16218-22. doi:10.1002/anie.201708744
- 31.Pfizer. Single dose study of PF-06815345 in healthy subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2016 Jan 13 [updated 2018 Sep 28; cited 2026 Oct 15]. Identifier: NCT02654899. Available from: https://clinicaltrials.gov/study/NCT02654899
- 32.Li W, Chang ST, Ward FR, Cate JHD. Selective inhibition of human translation termination by a drug-like compound. Nat Commun. 2020;11(1):4941. doi:10.1038/s41467-020-18765-2
- 33.Barhoosh H, Dixit A, Cochrane WG, Cavett V, Prince RN, Blair BO, et al. Activity-Based DNA-Encoded Library Screening for Selective Inhibitors of Eukaryotic Translation. ACS Cent Sci. 2024;10(10):1960-8. doi:10.1021/acscentsci.4c01218
- 34.Liaud N, Horlbeck MA, Gilbert LA, Gjoni K, Weissman JS, Cate JHD. Cellular response to small molecules that selectively stall protein synthesis by the ribosome. PLoS Genet. 2019;15(3):e1008057. doi:10.1371/journal.pgen.1008057
- 35.Gerashchenko MV, Gladyshev VN. Translation inhibitors cause abnormalities in ribosome profiling experiments. Nucleic Acids Res. 2014;42(17):e134. doi:10.1093/nar/gku671
- 36.Hussmann JA, Patchett S, Johnson A, Sawyer S, Press WH. Understanding Biases in Ribosome Profiling Experiments Reveals Signatures of Translation Dynamics in Yeast. PLoS Genet. 2015;11(12):e1005732. doi:10.1371/journal.pgen.1005732
- 37.Gerashchenko MV, Gladyshev VN. Ribonuclease selection for ribosome profiling. Nucleic Acids Res. 2017;45(2):e6. doi:10.1093/nar/gkw822
- 38.Mohammad F, Green R, Buskirk AR. A systematically-revised ribosome profiling method for bacteria reveals pauses at single-codon resolution. Elife. 2019;8:e42591. doi:10.7554/elife.42591
- 39.Robertson MJ, van Zundert GCP, Borrelli K, Skiniotis G. GemSpot: A Pipeline for Robust Modeling of Ligands into Cryo-EM Maps. Structure. 2020;28(6):707-716.e3. doi:10.1016/j.str.2020.04.018
- 40.Pfizer. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor [Internet]. 2016 Nov 1 [cited 2026 Oct 15]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococi zumab_its_investigational_pcsk9_inhibitor
- 41.Ernst JT, Thompson PA, Nilewski C, Sprengeler PA, Sperry S, Packard G, et al. Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020;63(11):5879-955. doi:10.1021/acs.jmedchem.0c00182
- 42.eFFECTOR Therapeutics. Current report: Form 8-K [Internet]. 2024 Apr 4 [cited 2026 Oct 15]. Available from: https://www.sec.gov/Archives/edgar/data/1828522/000119312524086664/d823667d8k.htm
- 43.eFFECTOR Therapeutics. Current report: Form 8-K [Internet]. 2024 Jun 24 [cited 2026 Oct 15]. Available from: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/d860453d8k.htm
- 44.Kuzuoglu-Ozturk D, Nguyen HG, Xue L, Figueredo E, Subramanyam V, Liu I, et al. Small-molecule RNA therapeutics to target prostate cancer. Cancer Cell. 2025;43(5):841-855.e8. doi:10.1016/j.ccell.2025.02.027
- 45.Boyer JA, Rosen EY, Sharma M, Dorso MA, Mai N, Amor C, et al. eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer. Proc Natl Acad Sci U S A. 2025;122(30):e2424286122. doi:10.1073/pnas.2424286122
- 46.Flores BN, Yu SB, Cohen IV, Fanok MH, Luan W, Maciuca RD, et al. Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial. Nat Commun. 2025;16(1):7690. doi:10.1038/s41467-025-63031-y
- 47.Paganoni S, Chibnik LB, Quintana M, Macklin EA, Detry MA, Vestrucci M, et al. DNL343 and Disease Progression in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(9):e2634809. doi:10.1001/jamanetworkopen.2026.34809
- 48.Denali Therapeutics. Denali Therapeutics announces topline results for regimen G evaluating eIF2B agonist DNL343 in the phase 2/3 HEALEY ALS Platform Trial [Internet]. 2025 Jan 6 [cited 2026 Oct 15]. Available from: https://investors.denalitherapeutics.com/node/10826/pdf
- 49.Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459-68. doi:10.1038/s41586-020-2286-9
- 50.eFFECTOR Therapeutics. eFFECTOR Therapeutics doses first patient with COVID-19 in phase 1b clinical trial evaluating zotatifin as a host-targeted antiviral agent [Internet]. 2021 Jul 22 [cited 2026 Oct 15]. Available from: https://www.globenewswire.com/news-release/2021/07/22/2267279/0/en/eFFECTOR-Therapeutics-Doses-First-Pati ent-with-COVID-19-in-Phase-1b-Clinical-Trial-Evaluating-Zotatifin-as-a-Host-Targeted-Antiviral-Agent.html
- 51.eFFECTOR Therapeutics. eFFECTOR Therapeutics announces positive top-line results from phase 1b clinical trial of zotatifin for the treatment of COVID [Internet]. 2023 Feb 21 [cited 2026 Oct 15]. Available from: https://www.globenewswire.com/news-release/2023/02/21/2612164/0/en/effector-therapeutics-announces-positive-t op-line-results-from-phase-1b-clinical-trial-of-zotatifin-for-the-treatment-of-covid.html
- 52.Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, et al. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci U S A. 2020;117(8):4053-60. doi:10.1073/pnas.1921649117
- 53.Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021;12(1):6468. doi:10.1038/s41467-021-26640-x
- 54.Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117(9):2567-76. doi:10.1182/blood-2010-07-295238
- 55.List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. N Engl J Med. 2006;355(14):1456-65. doi:10.1056/nejmoa061292
- 56.Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523(7559):183-8. doi:10.1038/nature14610
- 57.Wlodarski MW, Vlachos A, Farrar JE, Da Costa LM, Kattamis A, Dianzani I, et al. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. Lancet Haematol. 2024;11(5):e368-e382. doi:10.1016/S2352-3026(24)00063-2
- 58.Narla A, Vlachos A, Nathan DG. Diamond Blackfan anemia treatment: past, present, and future. Semin Hematol. 2011;48(2):117-23. doi:10.1053/j.seminhematol.2011.01.004
- 59.Taylor AM, Macari ER, Chan IT, Blair MC, Doulatov S, Vo LT, et al. Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. Sci Transl Med. 2020;12(566):eabb5831. doi:10.1126/scitranslmed.abb5831
- 60.Duncan BB, Lotter JL, Superata J, Barranta ME, Machado T, Darden I, et al. Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag. Br J Haematol. 2024;204(5):2077-85. doi:10.1111/bjh.19357
- 61.Payne EM, Virgilio M, Narla A, Sun H, Levine M, Paw BH, et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. Blood. 2012;120(11):2214-24. doi:10.1182/blood-2011-10-382986
- 62.Vlachos A, Atsidaftos E, Lababidi ML, Muir E, Rogers ZR, Alhushki W, et al. L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry. Pediatr Blood Cancer. 2020;67(12):e28748. doi:10.1002/pbc.28748
- 63.Rickgauer JP, Choi H, Moore AS, Denk W, Lippincott-Schwartz J. Structural dynamics of human ribosomes in situ reconstructed by exhaustive high-resolution template matching. Mol Cell. 2024;84(24):4912-4928.e7. doi:10.1016/j.molcel.2024.11.003
- 64.Cheng J, Wu C, Li J, Yang Q, Zhao M, Zhang X. Capturing eukaryotic ribosome dynamics in situ at high resolution. Nat Struct Mol Biol. 2025;32(4):698-708. doi:10.1038/s41594-024-01454-9
- 65.Zheng W, Zhang Y, Wang J, Wang S, Chai P, Bailey EJ, et al. Visualizing the translation landscape in human cells at high resolution. Nat Commun. 2025;16(1):10757. doi:10.1038/s41467-025-65795-9
- 66.Sundaramoorthy E, Leonard M, Mak R, Liao J, Fulzele A, Bennett EJ. ZNF598 and RACK1 Regulate Mammalian Ribosome-Associated Quality Control Function by Mediating Regulatory 40S Ribosomal Ubiquitylation. Mol Cell. 2017;65(4):751-760.e4. doi:10.1016/j.molcel.2016.12.026
- 67.Juszkiewicz S, Hegde RS. Initiation of Quality Control during Poly(A) Translation Requires Site-Specific Ribosome Ubiquitination. Mol Cell. 2017;65(4):743-750.e4. doi:10.1016/j.molcel.2016.11.039
- 68.Juszkiewicz S, Chandrasekaran V, Lin Z, Kraatz S, Ramakrishnan V, Hegde RS. ZNF598 Is a Quality Control Sensor of Collided Ribosomes. Mol Cell. 2018;72(3):469-481.e7. doi:10.1016/j.molcel.2018.08.037
- 69.Sinha NK, Ordureau A, Best K, Saba JA, Zinshteyn B, Sundaramoorthy E, et al. EDF1 coordinates cellular responses to ribosome collisions. Elife. 2020;9:e58828. doi:10.7554/elife.58828
- 70.Juszkiewicz S, Slodkowicz G, Lin Z, Freire-Pritchett P, Peak-Chew SY, Hegde RS. Ribosome collisions trigger cis-acting feedback inhibition of translation initiation. Elife. 2020;9:e60038. doi:10.7554/elife.60038
- 71.Hickey KL, Dickson K, Cogan JZ, Replogle JM, Schoof M, D'Orazio KN, et al. GIGYF2 and 4EHP Inhibit Translation Initiation of Defective Messenger RNAs to Assist Ribosome-Associated Quality Control. Mol Cell. 2020;79(6):950-962.e6. doi:10.1016/j.molcel.2020.07.007
- 72.Juszkiewicz S, Speldewinde SH, Wan L, Svejstrup JQ, Hegde RS. The ASC-1 Complex Disassembles Collided Ribosomes. Mol Cell. 2020;79(4):603-614.e8. doi:10.1016/j.molcel.2020.06.006
- 73.Goldman DH, Livingston NM, Movsik J, Wu B, Green R. Live-cell imaging reveals kinetic determinants of quality control triggered by ribosome stalling. Mol Cell. 2021;81(8):1830-1840.e8. doi:10.1016/j.molcel.2021.01.029
- 74.Pisareva VP, Skabkin MA, Hellen CU, Pestova TV, Pisarev AV. Dissociation by Pelota, Hbs1 and ABCE1 of mammalian vacant 80S ribosomes and stalled elongation complexes. EMBO J. 2011;30(9):1804-17. doi:10.1038/emboj.2011.93
- 75.Shao S, Brown A, Santhanam B, Hegde RS. Structure and assembly pathway of the ribosome quality control complex. Mol Cell. 2015;57(3):433-44. doi:10.1016/j.molcel.2014.12.015
- 76.Thrun A, Garzia A, Kigoshi-Tansho Y, Patil PR, Umbaugh CS, Dallinger T, et al. Convergence of mammalian RQC and C-end rule proteolytic pathways via alanine tailing. Mol Cell. 2021;81(10):2112-2122.e7. doi:10.1016/j.molcel.2021.03.004
- 77.Udagawa T, Seki M, Okuyama T, Adachi S, Natsume T, Noguchi T, et al. Failure to Degrade CAT-Tailed Proteins Disrupts Neuronal Morphogenesis and Cell Survival. Cell Rep. 2021;34(1):108599. doi:10.1016/j.celrep.2020.108599
- 78.Yip MCJ, Keszei AFA, Feng Q, Chu V, McKenna MJ, Shao S. Mechanism for recycling tRNAs on stalled ribosomes. Nat Struct Mol Biol. 2019;26(5):343-9. doi:10.1038/s41594-019-0211-4
- 79.Yip MCJ, Savickas S, Gygi SP, Shao S. ELAC1 Repairs tRNAs Cleaved during Ribosome-Associated Quality Control. Cell Rep. 2020;30(7):2106-2114.e5. doi:10.1016/j.celrep.2020.01.082
- 80.Meyer C, Garzia A, Morozov P, Molina H, Tuschl T. The G3BP1-Family-USP10 Deubiquitinase Complex Rescues Ubiquitinated 40S Subunits of Ribosomes Stalled in Translation from Lysosomal Degradation. Mol Cell. 2020;77(6):1193-1205.e5. doi:10.1016/j.molcel.2019.12.024
- 81.von der Malsburg K, Shao S, Hegde RS. The ribosome quality control pathway can access nascent polypeptides stalled at the Sec61 translocon. Mol Biol Cell. 2015;26(12):2168-80. doi:10.1091/mbc.e15-01-0040
- 82.Wang L, Xu Y, Rogers H, Saidi L, Noguchi CT, Li H, et al. UFMylation of RPL26 links translocation-associated quality control to endoplasmic reticulum protein homeostasis. Cell Res. 2020;30(1):5-20. doi:10.1038/s41422-019-0236-6
- 83.Desai N, Yang H, Chandrasekaran V, Kazi R, Minczuk M, Ramakrishnan V. Elongational stalling activates mitoribosome-associated quality control. Science. 2020;370(6520):1105-10. doi:10.1126/science.abc7782
- 84.Wu CC, Peterson A, Zinshteyn B, Regot S, Green R. Ribosome Collisions Trigger General Stress Responses to Regulate Cell Fate. Cell. 2020;182(2):404-416.e14. doi:10.1016/j.cell.2020.06.006
- 85.Yang H, Li Q, Stroup EK, Wang S, Ji Z. Widespread stable noncanonical peptides identified by integrated analyses of ribosome profiling and ORF features. Nat Commun. 2024;15(1):1932. doi:10.1038/s41467-024-46240-9
- 86.Deutsch EW, Kok LW, Mudge JM, Valls CF, Jungreis I, Ruiz-Orera J, et al. Expanding the human proteome with microproteins and peptideins. Nature. 2026;654(8119):813-25. doi:10.1038/s41586-026-10459-x
- 87.Murakami S, Olarerin-George AO, Liu JF, Zaccara S, Hawley B, Jaffrey SR. m6A alters ribosome dynamics to initiate mRNA degradation. Cell. 2025;188(14):3728-3743.e20. doi:10.1016/j.cell.2025.04.020
- 88.Karasik A, Jones GD, Guydosh NR. Stalled translation on transcripts cleaved by RNase L activates signaling important for innate immunity. RNA. 2026;32(6):945-61. doi:10.1261/rna.080699.125
- 89.Wan L, Juszkiewicz S, Blears D, Bajpe PK, Han Z, Faull P, et al. Translation stress and collided ribosomes are co-activators of cGAS. Mol Cell. 2021;81(13):2808-2822.e10. doi:10.1016/j.molcel.2021.05.018
- 90.Albers S, Allen EC, Bharti N, Davyt M, Joshi D, Perez-Garcia CG, et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo. Nature. 2023;618(7966):842-8. doi:10.1038/s41586-023-06133-1
- 91.Bharti N, Santos L, Davyt M, Behrmann S, Eichholtz M, Jimenez-Sanchez A, et al. Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations. Nat Commun. 2024;15(1):2957. doi:10.1038/s41467-024-47258-9
- 92.Pierce SE, Erwood S, Oye K, An M, Krasnow N, Zhang E, et al. Prime editing-installed suppressor tRNAs for disease-agnostic genome editing. Nature. 2025;648(8092):191-202. doi:10.1038/s41586-025-09732-2
- 93.Ren C, Song L, Hu M, Jin X, Liang L, Liu F, et al. AAV-delivered engineered suppressor tRNA rescues visual function in mice with an inherited retinal disease. Nat Commun. 2025;16(1):11185. doi:10.1038/s41467-025-66176-y
- 94.Xu M, Liu H, Wang J, Vieira AFC, Zhou X, Liu N, et al. An engineered UGA suppressor tRNA gene for disease-agnostic AAV delivery. Nat Biotechnol. 2026. doi:10.1038/s41587-025-02982-5
- 95.ARTAN Bio. ARTAN Bio closes $1 million seed round to advance its tRNA platform toward human studies [Internet]. 2026 Jul 1 [cited 2026 Oct 15]. Available from: https://www.prnewswire.com/news-releases/artan-bio-closes-1-million-seed-round-to-advance-its-trna-platform-tow ard-human-studies-302814741.html
- 96.Shao B, Yan J, Zhang J, Liu L, Chen Y, Buskirk AR. Riboformer: a deep learning framework for predicting context-dependent translation dynamics. Nat Commun. 2024;15(1):2011. doi:10.1038/s41467-024-46241-8
- 97.He J, Xiong L, Shi S, Li C, Chen K, Fang Q, et al. Deep learning prediction of ribosome profiling with Translatomer reveals translational regulation and interprets disease variants. Nat Mach Intell. 2024;6(11):1314-29. doi:10.1038/s42256-024-00915-6
- 98.Zheng D, Persyn L, Wang J, Liu Y, Ulloa-Montoya F, Cenik C, et al. Predicting the translation efficiency of messenger RNA in mammalian cells. Nat Biotechnol. 2026;44(5):783-96. doi:10.1038/s41587-025-02712-x
- 99.Ferguson L, Upton HE, Pimentel SC, Mok A, Lareau LF, Collins K, et al. Streamlined and sensitive mono- and di-ribosome profiling in yeast and human cells. Nat Methods. 2023;20(11):1704-15. doi:10.1038/s41592-023-02028-1
- 100.Meindl A, Romberger M, Lehmann G, Eichner N, Kleemann L, Wu J, et al. A rapid protocol for ribosome profiling of low input samples. Nucleic Acids Res. 2023;51(13):e68. doi:10.1093/nar/gkad459
- 101.Koubek J, Jetzinger K, Dror S, Irastortza-Olaziregi M, Frank D, Kotan I, et al. A simple, fast, and cost-efficient protocol for ultra-sensitive ribosome profiling. Nucleic Acids Res. 2025;53(17):gkaf902. doi:10.1093/nar/gkaf902
- 102.Calico Life Sciences. Calico Life Sciences announces fosigotifator granted breakthrough therapy designation by the US FDA for the treatment of vanishing white matter disease [Internet]. 2026 Jun 23 [cited 2026 Oct 15]. Available from: https://www.calicolabs.com/press/calico-life-sciences-announces-fosigotifator-granted-breakthrough-therapy-design ation-by-the-u-s-fda-for-the-treatment-of-vanishing-white-matter-disease/
- 103.ReviR Therapeutics. ReviR Therapeutics announces first participant dosed in phase 1 study and secures CDE clearance for two orphan indications in China, supporting future US expansion strategy [Internet]. 2026 Mar 2 [cited 2026 Oct 15]. Available from: https://www.prnewswire.com/news-releases/revir-therapeutics-announces-first-participant-dosed-in-phase-1-study-a nd-secures-cde-clearance-for-two-orphan-indications-in-china-supporting-future-us-expansion-strategy-302701040. html
- 104.McMahon M, Lianoglou S, Narayan S, Zhang J, Chen S, Li J, et al. Pharmacologic eIF2B Activation Rescues Neuropathy in CMT2 Subtypes by Normalizing the Integrated Stress Response. bioRxiv [Preprint]. 2026 Aug 6 [cited 2026 Oct 15]. doi:10.64898/2026.08.05.743063
- 105.Shilliday F, Gancedo-Rodrigo M, George G, Aibara S, Adhikari S, Ashraf SN, et al. A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response. Nat Commun. 2026;17(1):6110. doi:10.1038/s41467-026-72688-y
- 106.Dalwadi U, Subramanian A, Deal A, Conrad JE, Nadjsombati T, Venkatesh M, et al. Allosteric disordering of eIF2B regulates the integrated stress response. Nat Chem Biol. 2026. doi:10.1038/s41589-026-02256-4
- 107.Sidrauski C, Tsai JC, Kampmann M, Hearn BR, Vedantham P, Jaishankar P, et al. Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response. Elife. 2015;4:e07314. doi:10.7554/elife.07314
- 108.SJP Biotec. Our pipeline | Zotatifin & tomivosertib [Internet]. [date unknown] [cited 2026 Oct 15]. Available from: https://www.sjpbiotec.com/pipeline
- 109.eFFECTOR Therapeutics. Study of eFT226 in subjects with selected advanced solid tumor malignancies. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2019 Sep 17 [updated 2024 May 21; cited 2026 Oct 15]. Identifier: NCT04092673. Available from: https://clinicaltrials.gov/study/NCT04092673
- 110.M.D. Anderson Cancer Center. Zotatifin and EIF4A platinum helix inhibition in resistant advanced TNBC. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2026 Aug 25 [updated 2026 Sep 8; cited 2026 Oct 15]. Identifier: NCT07783659. Available from: https://clinicaltrials.gov/study/NCT07783659
- 111.Chu J, Hong NA, Masuda CA, Jenkins BV, Nelms KA, Goodnow CC, et al. A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. Proc Natl Acad Sci U S A. 2009;106(7):2097-103. doi:10.1073/pnas.0812819106
- 112.Dörrbaum AR, Kochen L, Langer JD, Schuman EM. Local and global influences on protein turnover in neurons and glia. Elife. 2018;7:e34202. doi:10.7554/elife.34202
- 113.Fusco CM, Desch K, Dörrbaum AR, Wang M, Staab A, Chan ICW, et al. Neuronal ribosomes exhibit dynamic and context-dependent exchange of ribosomal proteins. Nat Commun. 2021;12(1):6127. doi:10.1038/s41467-021-26365-x
- 114.Yoon BC, Jung H, Dwivedy A, O'Hare CM, Zivraj KH, Holt CE. Local Translation of Extranuclear Lamin B Promotes Axon Maintenance. Cell. 2012;148(4):752-64. doi:10.1016/j.cell.2011.11.064
- 115.Ciryam P, Tartaglia GG, Morimoto RI, Dobson CM, Vendruscolo M. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 2013;5(3):781-90. doi:10.1016/j.celrep.2013.09.043
- 116.Lee JW, Beebe K, Nangle LA, Jang J, Longo-Guess CM, Cook SA, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443(7107):50-5. doi:10.1038/nature05096
- 117.Kundra R, Ciryam P, Morimoto RI, Dobson CM, Vendruscolo M. Protein homeostasis of a metastable subproteome associated with Alzheimer's disease. Proc Natl Acad Sci U S A. 2017;114(28):E5703-E5711. doi:10.1073/pnas.1618417114
- 118.World Health Organization. Dementia [Internet]. 2026 [cited 2026 Oct 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
- 119.Centers for Disease Control and Prevention. National Amyotrophic Lateral Sclerosis (ALS) Registry [Internet]. [date unknown] [cited 2026 Oct 15]. Available from: https://www.cdc.gov/als/
- 120.National Institute of Neurological Disorders and Stroke. Amyotrophic lateral sclerosis (ALS) [Internet]. [reviewed 2026 Mar 13; cited 2026 Oct 15]. Available from: https://www.ninds.nih.gov/health-information/disorders/amyotrophic-lateral-sclerosis-als
- 121.National Institute on Aging. How is Alzheimer's disease treated? [Internet]. [reviewed 2023 Sep 12; cited 2026 Oct 15]. Available from: https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated
- 122.National Institute of Neurological Disorders and Stroke. Frontotemporal dementia and other frontotemporal disorders [Internet]. [reviewed 2026 Mar 13; cited 2026 Oct 15]. Available from: https://www.ninds.nih.gov/health-information/disorders/frontotemporal-dementia-and-other-frontotemporal-disorder s
- 123.Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008;456(7224):971-5. doi:10.1038/nature07449
- 124.Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, et al. Differential Requirements for eIF4E Dose in Normal Development and Cancer. Cell. 2015;162(1):59-71. doi:10.1016/j.cell.2015.05.049
- 125.Cenci S, Oliva L, Cerruti F, Milan E, Bianchi G, Raule M, et al. Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. J Leukoc Biol. 2012;92(5):921-31. doi:10.1189/jlb.1011497
- 126.Tsvetkov P, Adler J, Myers N, Biran A, Reuven N, Shaul Y. Oncogenic addiction to high 26S proteasome level. Cell Death Dis. 2018;9(7):773. doi:10.1038/s41419-018-0806-4
- 127.Kuzuoglu-Ozturk D, Aksoy O, Schmidt C, Lea R, Larson JD, Phelps RRL, et al. N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma. Cancer Res. 2023;83(1):130-40. doi:10.1158/0008-5472.can-22-0945
- 128.Khaket TP, Rimal S, Wang X, Wang X, Bhurtel S, Wu YC, et al. Ribosome stalling during c-myc translation presents actionable cancer cell vulnerability. PNAS Nexus. 2024;3(8):pgae321. doi:10.1093/pnasnexus/pgae321
- 129.Chatterjee S, Naeli P, Onar O, Simms N, Garzia A, Hackett A, et al. Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil. Nucleic Acids Res. 2024;52(20):12534-48. doi:10.1093/nar/gkae849
- 130.Kovalski JR, Sarioglu G, Subramanyam V, Hernandez G, Rademaker G, Oses-Prieto JA, et al. Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity. Nat Cell Biol. 2025;27(3):518-29. doi:10.1038/s41556-024-01604-7
- 131.Sfakianos AP, Raven RM, Smith T, Sun XM, Mulroney TE, Pizzinga M, et al. Inhibiting translation elongation by reducing eIF5A activity induces feedback inhibition of initiation, limiting tumour cell proliferation. Nat Commun. 2025;16(1):11486. doi:10.1038/s41467-025-66531-z
- 132.Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, et al. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021;27(3):819-30. doi:10.1158/1078-0432.ccr-20-2246
- 133.Howard TP, Oberlick EM, Rees MG, Arnoff TE, Pham MT, Brenan L, et al. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clin Cancer Res. 2020;26(18):4995-5006. doi:10.1158/1078-0432.ccr-19-2717
- 134.Allan EK, Holyoake TL, Craig AR, Jørgensen HG. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011;25(6):985-94. doi:10.1038/leu.2011.55
- 135.US Food and Drug Administration. SYNRIBO (omacetaxine mepesuccinate): prescribing information [Internet]. 2014 [cited 2026 Oct 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203585s003lbl.pdf
- 136.Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, et al. Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib. Clin Lymphoma Myeloma Leuk. 2013;13(5):584-91. doi:10.1016/j.clml.2013.03.020
- 137.Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer. 2015;121(10):1637-44. doi:10.1002/cncr.29240
- 138.Alvandi F, Kwitkowski VE, Ko CW, Rothmann MD, Ricci S, Saber H, et al. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist. 2014;19(1):94-9. doi:10.1634/theoncologist.2013-0077
- 139.Cesaro S, Donadieu J, Cipolli M, Dalle JH, Styczynski J, Masetti R, et al. Stem Cell Transplantation in Patients Affected by Shwachman-Diamond Syndrome: Expert Consensus and Recommendations From the EBMT Severe Aplastic Anaemia Working Party. Transplant Cell Ther. 2022;28(10):637-49. doi:10.1016/j.jtct.2022.07.010
- 140.Khajuria RK, Munschauer M, Ulirsch JC, Fiorini C, Ludwig LS, McFarland SK, et al. Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis. Cell. 2018;173(1):90-103.e19. doi:10.1016/j.cell.2018.02.036
- 141.Weis F, Giudice E, Churcher M, Jin L, Hilcenko C, Wong CC, et al. Mechanism of eIF6 release from the nascent 60S ribosomal subunit. Nat Struct Mol Biol. 2015;22(11):914-9. doi:10.1038/nsmb.3112
- 142.Jaako P, Faille A, Tan S, Wong CC, Escudero-Urquijo N, Castro-Hartmann P, et al. eIF6 rebinding dynamically couples ribosome maturation and translation. Nat Commun. 2022;13(1):1562. doi:10.1038/s41467-022-29214-7
- 143.Calo E, Gu B, Bowen ME, Aryan F, Zalc A, Liang J, et al. Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders. Nature. 2018;554(7690):112-7. doi:10.1038/nature25449
- 144.Ouspenskaia T, Law T, Clauser KR, Klaeger S, Sarkizova S, Aguet F, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209-17. doi:10.1038/s41587-021-01021-3
- 145.Weingarten-Gabbay S, Klaeger S, Sarkizova S, Pearlman LR, Chen DY, Gallagher KME, et al. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. Cell. 2021;184(15):3962-3980.e17. doi:10.1016/j.cell.2021.05.046
- 146.Thoms M, Buschauer R, Ameismeier M, Koepke L, Denk T, Hirschenberger M, et al. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. 2020;369(6508):1249-55. doi:10.1126/science.abc8665
- 147.Finkel Y, Gluck A, Nachshon A, Winkler R, Fisher T, Rozman B, et al. SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature. 2021;594(7862):240-5. doi:10.1038/s41586-021-03610-3
- 148.GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199-226. doi:10.1016/S0140-6736(24)01867-1
- 149.World Health Organization. Global antibiotic resistance surveillance report 2025 [Internet]. 2025 [cited 2026 Oct 15]. Available from: https://www.who.int/publications/i/item/9789240116337
- 150.Butler MS, Capon RJ. Natural product inspired antibiotics approved for human use – 1943 to 2025. Nat Prod Rep. 2026;43(5):813-96. doi:10.1039/d5np00067j
- 151.Mitcheltree MJ, Pisipati A, Syroegin EA, Silvestre KJ, Klepacki D, Mason JD, et al. A synthetic antibiotic class overcoming bacterial multidrug resistance. Nature. 2021;599(7885):507-12. doi:10.1038/s41586-021-04045-6
- 152.Wu KJY, Tresco BIC, Ramkissoon A, Aleksandrova EV, Syroegin EA, See DNY, et al. An antibiotic preorganized for ribosomal binding overcomes antimicrobial resistance. Science. 2024;383(6684):721-6. doi:10.1126/science.adk8013
- 153.Tresco BIC, Wu KJY, Ramkissoon A, Aleksandrova EV, Purdy M, See DNY, et al. Discovery of a fluorinated macrobicyclic antibiotic through chemical synthesis. Nat Chem. 2025;17(4):582-9. doi:10.1038/s41557-025-01738-7
- 154.Llano-Sotelo B, Hickerson RP, Lancaster L, Noller HF, Mankin AS. Fluorescently labeled ribosomes as a tool for analyzing antibiotic binding. RNA. 2009;15(8):1597-604. doi:10.1261/rna.1681609
- 155.David-Eden H, Mankin AS, Mandel-Gutfreund Y. Structural signatures of antibiotic binding sites on the ribosome. Nucleic Acids Res. 2010;38(18):5982-94. doi:10.1093/nar/gkq411
- 156.Veenbaas SD, Koehn JT, Irving PS, Lama NN, Weeks KM. Ligand-binding pockets in RNA and where to find them. Proc Natl Acad Sci U S A. 2025;122(17):e2422346122. doi:10.1073/pnas.2422346122
- 157.Koller TO, Berger MJ, Morici M, Paternoga H, Bulatov T, Di Stasi A, et al. Paenilamicins are context-specific translocation inhibitors of protein synthesis. Nat Chem Biol. 2024;20(12):1691-700. doi:10.1038/s41589-024-01752-9
- 158.Kaur M, Travin DY, Berger MJ, Jangra M, Morici M, Safdari HA, et al. A natural depsipeptide antibiotic binds the E-site of the bacterial ribosome. Nature. 2026;655(8123):737-46. doi:10.1038/s41586-026-10589-2
- 159.Safdari HA, Morici M, Sanchez-Castro A, Dallapè A, Paternoga H, Giuliodori AM, et al. The translation inhibitors kasugamycin, edeine and GE81112 target distinct steps during 30S initiation complex formation. Nat Commun. 2025;16(1):2470. doi:10.1038/s41467-025-57731-8
- 160.Stokes JM, Davis JH, Mangat CS, Williamson JR, Brown ED. Discovery of a small molecule that inhibits bacterial ribosome biogenesis. Elife. 2014;3:e03574. doi:10.7554/eLife.03574
- 161.Stokes JM, Selin C, Cardona ST, Brown ED. Chemical Inhibition of Bacterial Ribosome Biogenesis Shows Efficacy in a Worm Infection Model. Antimicrob Agents Chemother. 2015;59(5):2918-20. doi:10.1128/aac.04690-14
- 162.Aron ZD, Mehrani A, Hoffer ED, Connolly KL, Srinivas P, Torhan MC, et al. trans-Translation inhibitors bind to a novel site on the ribosome and clear Neisseria gonorrhoeae in vivo. Nat Commun. 2021;12(1):1799. doi:10.1038/s41467-021-22012-7
- 163.Varshney A, Alumasa JN, Miller A, Keiler KC. A trans-translation inhibitor that targets ribosomal protein bL12 kills Mycobacterium tuberculosis. J Bacteriol. 2025;207(10):e0023625. doi:10.1128/jb.00236-25
- 164.Park J, Lee J, Kim JH, Lee J, Park H, Lim C. ZNF598 co-translationally titrates poly(GR) protein implicated in the pathogenesis of C9ORF72-associated ALS/FTD. Nucleic Acids Res. 2021;49(19):11294-311. doi:10.1093/nar/gkab834
- 165.Li S, Wu Z, Tantray I, Li Y, Chen S, Dong J, et al. Quality-control mechanisms targeting translationally stalled and C-terminally extended poly(GR) associated with ALS/FTD. Proc Natl Acad Sci U S A. 2020;117(40):25104-15. doi:10.1073/pnas.2005506117
- 166.Tseng YJ, Krans A, Malik I, Deng X, Yildirim E, Ovunc S, et al. Ribosomal quality control factors inhibit repeat-associated non-AUG translation from GC-rich repeats. Nucleic Acids Res. 2024;52(10):5928-49. doi:10.1093/nar/gkae137
- 167.Viera Ortiz AP, Cajka G, Olatunji OA, Mikytuck B, Shalem O, Lee EB. Impaired ribosome-associated quality control of C9orf72 arginine-rich dipeptide-repeat proteins. Brain. 2023;146(7):2897-912. doi:10.1093/brain/awac479
- 168.Kriachkov V, Ormsby AR, Kusnadi EP, McWilliam HEG, Mintern JD, Amarasinghe SL, et al. Arginine-rich C9ORF72 ALS proteins stall ribosomes in a manner distinct from a canonical ribosome-associated quality control substrate. J Biol Chem. 2023;299(1):102774. doi:10.1016/j.jbc.2022.102774
- 169.Latallo MJ, Wang S, Dong D, Nelson B, Livingston NM, Wu R, et al. Single-molecule imaging reveals distinct elongation and frameshifting dynamics between frames of expanded RNA repeats in C9ORF72-ALS/FTD. Nat Commun. 2023;14(1):5581. doi:10.1038/s41467-023-41339-x
- 170.Geng J, Li S, Li Y, Wu Z, Bhurtel S, Rimal S, et al. Stalled translation by mitochondrial stress upregulates a CNOT4-ZNF598 ribosomal quality control pathway important for tissue homeostasis. Nat Commun. 2024;15(1):1637. doi:10.1038/s41467-024-45525-3
- 171.Rimal S, Li Y, Vartak R, Geng J, Tantray I, Li S, et al. Inefficient quality control of ribosome stalling during APP synthesis generates CAT-tailed species that precipitate hallmarks of Alzheimer's disease. Acta Neuropathol Commun. 2021;9(1):169. doi:10.1186/s40478-021-01268-6
- 172.Qin F, Cao R, Bai X, Yuan J, Sun W, Zheng Y, et al. Listerin Alleviates Alzheimer's Disease through IRE1‐mediated Decay of TLR4 mRNA. Adv Sci (Weinh). 2025;12(32):e14956. doi:10.1002/advs.202414956
- 173.Ahmed A, Wang M, Bergant G, Maroofian R, Zhao R, Alfadhel M, et al. Biallelic loss-of-function variants in NEMF cause central nervous system impairment and axonal polyneuropathy. Hum Genet. 2021;140(4):579-92. doi:10.1007/s00439-020-02226-3
- 174.Endo R, Chen YK, Burke J, Takashima N, Suryawanshi N, Hui KK, et al. Dysregulation of ribosome-associated quality control elicits cognitive disorders via overaccumulation of TTC3. Proc Natl Acad Sci U S A. 2023;120(12):e2211522120. doi:10.1073/pnas.2211522120
- 175.Ishimura R, Nagy G, Dotu I, Zhou H, Yang XL, Schimmel P, et al. Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. Science. 2014;345(6195):455-9. doi:10.1126/science.1249749
- 176.Terrey M, Adamson SI, Gibson AL, Deng T, Ishimura R, Chuang JH, et al. GTPBP1 resolves paused ribosomes to maintain neuronal homeostasis. Elife. 2020;9:e62731. doi:10.7554/eLife.62731
- 177.Huso VL, Niu S, Catipovic MA, Saba JA, Denk T, Park E, et al. ZAK activation at the collided ribosome. Nature. 2026;649(8098):1051-60. doi:10.1038/s41586-025-09772-8
- 178.Vind AC, Martínez JF, Wu Z, Bugai A, Mordente K, Abis G, et al. Mechanism of RACK1-dependent ZAKα activation at stalled and collided ribosomes. Mol Cell. 2026;86(12):2341-2357.e10. doi:10.1016/j.molcel.2026.04.034
- 179.Park J, Kim SH, Park J, Park H, Kim H, Kim DW, et al. BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia. Leukemia. 2026;40(5):955-69. doi:10.1038/s41375-026-02916-3
- 180.Xie S, Liu H, Zhu S, Chen Z, Wang R, Zhang W, et al. Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway. Cancer Gene Ther. 2024;31(10):1486-97. doi:10.1038/s41417-024-00818-z
- 181.Li S, Chen M, Zheng S, Abudourexiti W, Zhu F, Wang Z, et al. ZAKα Induces Pyroptosis of Colonic Epithelium Via the Caspase-11/GSDMD Pathway to Aggravate Colitis. Inflammation. 2025;48(5):3235-51. doi:10.1007/s10753-025-02262-z
- 182.Vind AC, Wu Z, Firdaus MJ, Snieckute G, Toh GA, Jessen M, et al. The ribotoxic stress response drives acute inflammation, cell death, and epidermal thickening in UV-irradiated skin in vivo. Mol Cell. 2024;84(24):4774-4789.e9. doi:10.1016/j.molcel.2024.10.044
- 183.Requião RD, Lima-Silva LF, Estevão P, Costa WLG, Zani NC, Vasconcelos IC, et al. The integrated stress response kinase GCN2 prevents ZAKα-Dependent inflammatory hyperactivation in macrophages. J Biol Chem. 2026;302(10):113452. doi:10.1016/j.jbc.2026.113452
- 184.Hsu JC, Laurent-Rolle M, Pawlak JB, Xia H, Kunte A, Hee JS, et al. Viperin triggers ribosome collision-dependent translation inhibition to restrict viral replication. Mol Cell. 2022;82(9):1631-1642.e6. doi:10.1016/j.molcel.2022.02.031
- 185.Liu J, Nagy N, Ayala-Torres C, Aguilar-Alonso F, Morais-Esteves F, Xu S, et al. Remodeling of the ribosomal quality control and integrated stress response by viral ubiquitin deconjugases. Nat Commun. 2023;14(1):8315. doi:10.1038/s41467-023-43946-0
- 186.Xi J, Snieckute G, Martínez JF, Arendrup FSW, Asthana A, Gaughan C, et al. Initiation of a ZAKα-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L. Cell Rep. 2024;43(4):113998. doi:10.1016/j.celrep.2024.113998
- 187.Prindle V, Richardson AE, Sher KR, Kongpachith S, Kentala K, Petiwala S, et al. Synthetic lethality of mRNA quality control complexes in cancer. Nature. 2025;638(8052):1095-103. doi:10.1038/s41586-024-08398-6
- 188.Zhang H, Tonini MR, Martires LCM, Jenkins HN, Pratt CB, Gordon EN, et al. Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer. Biochim Biophys Acta Mol Cell Res. 2026;1873(1):120070. doi:10.1016/j.bbamcr.2025.120070
- 189.Nicholson HE, Whittington DA, Bruzzese FJ, Lazarides K, Martires LCM, Tonini MR, et al. TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers. Cancer Discov. 2026;16(9):1884-902. doi:10.1158/2159-8290.CD-26-0040
- 190.Iwasaki S, Floor SN, Ingolia NT. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. Nature. 2016;534(7608):558-61. doi:10.1038/nature17978
- 191.Iwasaki S, Iwasaki W, Takahashi M, Sakamoto A, Watanabe C, Shichino Y, et al. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA. Mol Cell. 2019;73(4):738-748.e9. doi:10.1016/j.molcel.2018.11.026
- 192.Das I, Krzyzosiak A, Schneider K, Wrabetz L, D'Antonio M, Barry N, et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science. 2015;348(6231):239-42. doi:10.1126/science.aaa4484
- 193.Mort M, Ivanov D, Cooper DN, Chuzhanova NA. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008;29(8):1037-47. doi:10.1002/humu.20763
- 194.Roy B, Leszyk JD, Mangus DA, Jacobson A. Nonsense suppression by near-cognate tRNAs employs alternative base pairing at codon positions 1 and 3. Proc Natl Acad Sci U S A. 2015;112(10):3038-43. doi:10.1073/pnas.1424127112
- 195.Roy B, Friesen WJ, Tomizawa Y, Leszyk JD, Zhuo J, Johnson B, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci U S A. 2016;113(44):12508-13. doi:10.1073/pnas.1605336113
- 196.Ng MY, Li H, Ghelfi MD, Goldman YE, Cooperman BS. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms. Proc Natl Acad Sci U S A. 2021;118(2):e2020599118. doi:10.1073/pnas.2020599118
- 197.PTC Therapeutics. PTC Therapeutics announces results from pivotal phase 3 clinical trial of ataluren in patients living with nonsense mutation cystic fibrosis [Internet]. 2017 Mar 2 [cited 2026 Oct 15]. Available from: https://www.sec.gov/Archives/edgar/data/1070081/000107008117000055/exhibit991.htm
- 198.European Medicines Agency. Translarna [Internet]. [date unknown] [cited 2026 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/translarna
- 199.PTC Therapeutics. PTC Therapeutics provides regulatory update on Translarna [Internet]. 2026 Feb 12 [cited 2026 Oct 15]. Available from: https://www.sec.gov/Archives/edgar/data/1070081/000110465926014414/tmb-20260212xex99d1.htm
- 200.Huang S, Bhattacharya A, Ghelfi MD, Li H, Fritsch C, Chenoweth DM, et al. Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination. Nat Commun. 2022;13(1):2413. doi:10.1038/s41467-022-30080-6
- 201.Coelho JPL, Yip MCJ, Oltion K, Taunton J, Shao S. The eRF1 degrader SRI-41315 acts as a molecular glue at the ribosomal decoding center. Nat Chem Biol. 2024;20(7):877-84. doi:10.1038/s41589-023-01521-0
- 202.Bhat SY, Bhattacharya A, Li H, Cui X, Lueck JD, Goldman YE, et al. Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases. Nucleic Acids Res. 2025;53(6):gkaf216. doi:10.1093/nar/gkaf216
- 203.Wang J, Zhang Y, Mendonca CA, Yukselen O, Muneeruddin K, Ren L, et al. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature. 2022;604(7905):343-8. doi:10.1038/s41586-022-04533-3
- 204.Wu J, Subbaiah KCV, Xie LH, Jiang F, Khor ES, Mickelsen D, et al. Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis. Circ Res. 2020;127(6):827-46. doi:10.1161/circresaha.119.315999
- 205.Oliveira MM, Lourenco MV, Longo F, Kasica NP, Yang W, Ureta G, et al. Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. Sci Signal. 2021;14(668):eabc5429. doi:10.1126/scisignal.abc5429
- 206.Kasica NP, Zhou X, Yang Q, Wang X, Yang W, Zimmermann HR, et al. Antagonists targeting eEF2 kinase rescue multiple aspects of pathophysiology in Alzheimer’s disease model mice. J Neurochem. 2022;160(5):524-39. doi:10.1111/jnc.15562
- 207.Krukowski K, Nolan A, Frias ES, Boone M, Ureta G, Grue K, et al. Small molecule cognitive enhancer reverses age-related memory decline in mice. Elife. 2020;9:e62048. doi:10.7554/eLife.62048
- 208.Piol D, Khalil B, Robberechts T, Killian T, Georgopoulou M, Partel G, et al. Axonal Eif5a hypusination controls local translation and mitigates defects in FUS-ALS. Nat Neurosci. 2026;29(1):53-66. doi:10.1038/s41593-025-02101-2
- 209.Zuko A, Mallik M, Thompson R, Spaulding EL, Wienand AR, Been M, et al. tRNA overexpression rescues peripheral neuropathy caused by mutations in tRNA synthetase. Science. 2021;373(6559):1161-6. doi:10.1126/science.abb3356
- 210.Zhang H, Alsaleh G, Feltham J, Sun Y, Napolitano G, Riffelmacher T, et al. Polyamines Control eIF5A Hypusination, TFEB Translation, and Autophagy to Reverse B Cell Senescence. Mol Cell. 2019;76(1):110-125.e9. doi:10.1016/j.molcel.2019.08.005
- 211.Zhou J, Pang J, Tripathi M, Ho JP, Widjaja AA, Shekeran SG, et al. Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nat Commun. 2022;13(1):5202. doi:10.1038/s41467-022-32788-x
- 212.Watanabe S, Markov NS, Lu Z, Piseaux Aillon R, Soberanes S, Runyan CE, et al. Resetting proteostasis with ISRIB promotes epithelial differentiation to attenuate pulmonary fibrosis. Proc Natl Acad Sci U S A. 2021;118(20):e2101100118. doi:10.1073/pnas.2101100118
- 213.Nan J, He X, Liu X, Ran J, Chen J, Li P, et al. Single-cell perturbations decipher ribosomal stress-surveillance regulators in type 2 diabetes. Nat Metab. 2026;8(1):139-58. doi:10.1038/s42255-025-01407-6
- 214.Li J, Rouse SL, Matthews IR, Park Y, Eltawil Y, Sherr EH, et al. Modulating the unfolded protein response with ISRIB mitigates cisplatin ototoxicity. Sci Rep. 2024;14(1):22382. doi:10.1038/s41598-024-70561-w
- 215.Giménez Y, Palacios M, Sánchez-Domínguez R, Zorbas C, Peral J, Puzik A, et al. Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for Diamond Blackfan anemia. JCI Insight. 2024;9(10):e171650. doi:10.1172/jci.insight.171650
- 216.Oyarbide U, Bezzerri V, Staton M, Boni C, Shah A, Cipolli M, et al. Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome. J Clin Invest. 2025;135(8):e187778. doi:10.1172/JCI187778
- 217.Aviner R, Lee TT, Masto VB, Li KH, Andino R, Frydman J. Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington’s disease. Nat Cell Biol. 2024;26(6):892-902. doi:10.1038/s41556-024-01414-x
- 218.Dong D, Zhang Z, Li Y, Latallo MJ, Wang S, Nelson B, et al. Poly-GR repeats associated with ALS/FTD gene C9ORF72 impair translation elongation and induce a ribotoxic stress response in neurons. Sci Signal. 2024;17(848):eadl1030. doi:10.1126/scisignal.adl1030
- 219.De La Cruz AC, Tisdale G, Nakayama E, Huang Z, Sinha NK, Green R, et al. Single-protein/RNA imaging reveals ZNF598 as a limiting factor in resolving collided ribosomes. EMBO J. 2025;44(18):5215-32. doi:10.1038/s44318-025-00523-z
- 220.Li W, Scheel T, Shen PS. Mechanism of nascent chain removal by the ribosome-associated quality control complex. Nat Commun. 2025;16(1):5792. doi:10.1038/s41467-025-61235-w
- 221.Inada T. Ribosome-associated quality control and related mechanisms. Nat Struct Mol Biol. 2026;33(3):394-407. doi:10.1038/s41594-026-01771-1
- 222.Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell. 2007;6(1):95-110. doi:10.1111/j.1474-9726.2006.00267.x